Cargando…

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer

LESSONS LEARNED. The combination of standard dose abiraterone acetate and BEZ235, a pan‐class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC. Although the clinical development of BEZ235 has been discontinued in prostate cancer, agents that more selectively target P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Xiao X., Hsieh, Andrew C., Kim, Won, Friedlander, Terence, Lin, Amy M., Louttit, Mirela, Ryan, Charles J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2017
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423513/ https://www.ncbi.nlm.nih.gov/pubmed/28314838 http://dx.doi.org/10.1634/theoncologist.2016-0432

Ejemplares similares

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
por: Carlo, Maria I., et al.
Publicado: (2016)

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2018)

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
por: Salazar, Ramon, et al.
Publicado: (2017)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
por: Li, Liangqing, et al.
Publicado: (2018)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011)

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
por: Li, Chuntuan, et al.
Publicado: (2015)

Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
por: Li, Jie, et al.
Publicado: (2021)

BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
por: Füreder, Thorsten, et al.
Publicado: (2010)

Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012)

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells
por: Oh, Iljoong, et al.
Publicado: (2016)

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
por: Meng, Wei, et al.
Publicado: (2019)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
por: Nyfeler, Beat, et al.
Publicado: (2012)

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
por: Zou, Hong, et al.
Publicado: (2016)

Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
por: Piao, Junjie, et al.
Publicado: (2016)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
por: Xin, Pengliang, et al.
Publicado: (2017)

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
por: Wise-Draper, Trisha M., et al.
Publicado: (2017)

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
por: Lang, Fabian, et al.
Publicado: (2020)

NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
por: Li, Bihui, et al.
Publicado: (2022)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
por: Chen, Liyan, et al.
Publicado: (2017)

Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
por: Chen, Yu-Hsuan, et al.
Publicado: (2019)

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
por: Venkannagari, Sreedhar, et al.
Publicado: (2012)

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway
por: Tang, Xiaolong, et al.
Publicado: (2020)

Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway
por: Tang, Xiaolong, et al.
Publicado: (2021)

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Liaw, Bobby C, et al.
Publicado: (2022)

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions
por: Kuger, Sebastian, et al.
Publicado: (2014)

The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway
por: Luo, Hui, et al.
Publicado: (2019)

The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma
por: Wu, Ning, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
por: Wu, Yi-Ying, et al.
Publicado: (2019)

Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell
por: Zhu, Hao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p1vg6d2lro5fkn533513vmil9u